{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:33Z","timestamp":1792511613983,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s11926-010-0098-x","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T02:45:28Z","timestamp":1272595528000},"page":"177-185","source":"Crossref","is-referenced-by-count":17,"title":["Cancer Therapies and Bone Health"],"prefix":"10.1007","volume":"12","author":[{"given":"Mimi I.","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Gagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,1]]},"reference":[{"key":"98_CR1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1196\/annals.1365.035","volume":"1092","author":"DJ Hadjidakis","year":"2006","unstructured":"Hadjidakis DJ, Androulakis II: Bone remodeling. Ann N Y Acad Sci 2006, 1092:385\u2013396.","journal-title":"Ann N Y Acad Sci"},{"key":"98_CR2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jocd.2008.04.003","volume":"11","author":"NB Watts","year":"2008","unstructured":"\u2022\u2022 Watts NB, Lewiecki EM, Miller PD, Baim S: National Osteoporosis Foundation 2008 Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom 2008, 11:473\u2013477. This is an updated guideline for clinical practice in the evaluation of osteoporosis and fracture risk.","journal-title":"J Clin Densitom"},{"key":"98_CR3","first-page":"129","volume":"134","author":"BL Riggs","year":"1988","unstructured":"Riggs BL, Melton LJ 3rd: Osteoporosis and age-related fracture syndromes. Ciba Found Symp 1988, 134:129\u2013142.","journal-title":"Ciba Found Symp"},{"key":"98_CR4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/er.2004-0001","volume":"26","author":"K Janssens","year":"2005","unstructured":"Janssens K, ten Dijke P, Janssens S, Van Hul W: Transforming growth factor-beta1 to the bone. Endocr Rev 2005, 26:743\u2013774.","journal-title":"Endocr Rev"},{"key":"98_CR5","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/endo.140.9.7131","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Khosla S, Dunstan CR, et al.: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367\u20134370.","journal-title":"Endocrinology"},{"key":"98_CR6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","volume":"79","author":"JA Kanis","year":"1999","unstructured":"Kanis JA, McCloskey EV, Powles T, et al.: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179\u20131181.","journal-title":"Br J Cancer"},{"key":"98_CR7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Bassford TL, et al.: Fracture risk among breast cancer survivors: results from the Women\u2019s Health Initiative Observational Study. Arch Intern Med 2005, 165:552\u2013558.","journal-title":"Arch Intern Med"},{"key":"98_CR8","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, et al.: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656\u20133661.","journal-title":"J Clin Endocrinol Metab"},{"key":"98_CR9","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/01.ju.0000059281.67667.97","volume":"169","author":"LJ Melton 3rd","year":"2003","unstructured":"Melton LJ 3rd, Alothman KI, Khosla S, et al.: Fracture risk following bilateral orchiectomy. J Urol 2003, 169:1747\u20131750.","journal-title":"J Urol"},{"key":"98_CR10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","volume":"168","author":"MG Oefelein","year":"2002","unstructured":"Oefelein MG, Ricchiuti V, Conrad W, Resnick MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168:1005\u20131007.","journal-title":"J Urol"},{"key":"98_CR11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","volume":"24","author":"L Vehmanen","year":"2006","unstructured":"Vehmanen L, Elomaa I, Blomqvist C, Saarto T: Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006, 24:675\u2013680.","journal-title":"J Clin Oncol"},{"key":"98_CR12","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652\u20131662.","journal-title":"J Natl Cancer Inst"},{"key":"98_CR13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"\u2022 Coleman RE, Banks LM, Girgis SI, et al.: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119\u2013127. This study found that patients treated with exemestane were at greater risk for clinical fractures than those treated with tamoxifen.","journal-title":"Lancet Oncol"},{"key":"98_CR14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/157488706778250096","volume":"1","author":"A Howell","year":"2006","unstructured":"Howell A: The \u2018Arimidex\u2019, Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer. Rev Recent Clin Trials 2006, 1:207\u2013215.","journal-title":"Rev Recent Clin Trials"},{"key":"98_CR15","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"EA Perez","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI, et al.: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629\u20133635.","journal-title":"J Clin Oncol"},{"key":"98_CR16","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"A Sverrisd\u00f3ttir","year":"2004","unstructured":"Sverrisd\u00f3ttir A, Fornander T, Jacobsson H, et al.: Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004, 22:3694\u20133699.","journal-title":"J Clin Oncol"},{"key":"98_CR17","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","volume":"91","author":"MR Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Fallon MA, et al.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238\u20132245.","journal-title":"Cancer"},{"key":"98_CR18","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/10428190701471973","volume":"48","author":"ME Cabanillas","year":"2007","unstructured":"\u2022 Cabanillas ME, Lu H, Fang S, Du XL: Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma 2007, 48:1514\u20131521. This is a study using the SEER-Medicare data to evaluate the long-term effects of chemotherapies on bone health in a large population of people who survived NHL. It demonstrated that prior chemotherapy use in this population is associated with higher risks of osteoporosis and fracture.","journal-title":"Leuk Lymphoma"},{"key":"98_CR19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1203\/00006450-199904010-00014","volume":"45","author":"JT Warner","year":"1999","unstructured":"Warner JT, Evans WD, Webb DK, et al.: Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res 1999, 45:544\u2013551.","journal-title":"Pediatr Res"},{"key":"98_CR20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/bjc.1994.308","volume":"70","author":"SJ Holmes","year":"1994","unstructured":"Holmes SJ, Whitehouse RW, Clark ST, et al.: Reduced bone mineral density in men following chemotherapy for Hodgkin\u2019s disease. Br J Cancer 1994, 70:371\u2013375.","journal-title":"Br J Cancer"},{"key":"98_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0002-9343(88)90504-9","volume":"85","author":"JR Redman","year":"1988","unstructured":"Redman JR, Bajorunas DR, Wong G, et al.: Bone mineralization in women following successful treatment of Hodgkin\u2019s disease. Am J Med 1988, 85:65\u201372.","journal-title":"Am J Med"},{"key":"98_CR22","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14:1718\u20131729.","journal-title":"J Clin Oncol"},{"key":"98_CR23","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306\u20133311.","journal-title":"J Clin Oncol"},{"key":"98_CR24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00005650-199308000-00006","volume":"31","author":"AL Potosky","year":"1993","unstructured":"Potosky AL, Riley GF, Lubitz JD, et al.: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993, 31:732\u2013748.","journal-title":"Med Care"},{"key":"98_CR25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/0041-008X(91)90310-B","volume":"107","author":"DR Plowchalk","year":"1991","unstructured":"Plowchalk DR, Mattison DR: Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicol Appl Pharmacol 1991, 107:472\u2013481.","journal-title":"Toxicol Appl Pharmacol"},{"key":"98_CR26","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1200\/JCO.1996.14.11.2923","volume":"14","author":"C Bokemeyer","year":"1996","unstructured":"Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996, 14:2923\u20132932.","journal-title":"J Clin Oncol"},{"key":"98_CR27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/1097-0142(197003)25:3<580::AID-CNCR2820250313>3.0.CO;2-M","volume":"25","author":"AH Ragab","year":"1970","unstructured":"Ragab AH, Frech RS, Vietti TJ: Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 1970, 25:580\u2013585.","journal-title":"Cancer"},{"key":"98_CR28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1148\/radiology.202.2.9015088","volume":"202","author":"K Ecklund","year":"1997","unstructured":"Ecklund K, Laor T, Goorin AM, et al.: Methotrexate osteopathy in patients with osteosarcoma. Radiology 1997, 202:543\u2013547.","journal-title":"Radiology"},{"key":"98_CR29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jor.1100080207","volume":"8","author":"OS Nilsson","year":"1990","unstructured":"Nilsson OS, Bauer HC, Brostrom LA: Comparison of the effects of adriamycin and methotrexate on orthotopic and induced heterotopic bone in rats. J Orthop Res 1990, 8:199\u2013204.","journal-title":"J Orthop Res"},{"key":"98_CR30","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2004.04.199","volume":"22","author":"K Mandel","year":"2004","unstructured":"Mandel K, Atkinson S, Barr RD, Pencharz P: Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 2004, 22:1215\u20131221.","journal-title":"J Clin Oncol"},{"key":"98_CR31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000146262","volume":"127","author":"TM Wang","year":"1986","unstructured":"Wang TM, Shih C: Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. Acta Anat (Basel) 1986, 127:93\u201399.","journal-title":"Acta Anat (Basel)"},{"key":"98_CR32","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1158\/1078-0432.CCR-06-1382","volume":"12","author":"JE Brown","year":"2006","unstructured":"Brown JE, Ellis SP, Silcocks P, et al.: Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res 2006, 12:6480\u20136486.","journal-title":"Clin Cancer Res"},{"key":"98_CR33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF00445929","volume":"148","author":"J Smeitink","year":"1988","unstructured":"Smeitink J, Verreussel M, Schr\u00f6der C, Lippens R: Nephrotoxicity associated with ifosfamide. Eur J Pediatr 1988, 148:164\u2013166.","journal-title":"Eur J Pediatr"},{"key":"98_CR34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3476(05)80557-8","volume":"117","author":"CD Burk","year":"1990","unstructured":"Burk CD, Restaino I, Kaplan BS, Meadows AT: Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr 1990, 117:331\u2013335.","journal-title":"J Pediatr"},{"key":"98_CR35","first-page":"219","volume":"6","author":"M K\u00f6ther","year":"1992","unstructured":"K\u00f6ther M, Schindler J, Oette K, Berthold F: Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide. In Vivo 1992, 6:219\u2013221.","journal-title":"In Vivo"},{"key":"98_CR36","first-page":"1527","volume":"63","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Schilsky R, Reichert CM, et al.: Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979, 63:1527\u20131531.","journal-title":"Cancer Treat Rep"},{"key":"98_CR37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2106\/00004623-198466040-00016","volume":"66","author":"GE Friedlaender","year":"1984","unstructured":"Friedlaender GE, Tross RB, Doganis AC, et al.: Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am 1984, 66:602\u2013607.","journal-title":"J Bone Joint Surg Am"},{"key":"98_CR38","first-page":"67","volume":"28","author":"CA Glackin","year":"1992","unstructured":"Glackin CA, Murray EJ, Murray SS: Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cells. Biochem Int 1992, 28:67\u201375.","journal-title":"Biochem Int"},{"key":"98_CR39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02405331","volume":"36","author":"G Kohler","year":"1984","unstructured":"Kohler G, Shen V, Peck WA: Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cells. Calcif Tissue Int 1984, 36:279\u2013284.","journal-title":"Calcif Tissue Int"},{"key":"98_CR40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2141.2003.04303.x","volume":"121","author":"MK Gandhi","year":"2003","unstructured":"Gandhi MK, Lekamwasam S, Inman I, et al.: Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 2003, 121:462\u2013468.","journal-title":"Br J Haematol"},{"key":"98_CR41","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1210\/jc.2002-020800","volume":"87","author":"L Tauchmanova","year":"2002","unstructured":"Tauchmanova L, Serio B, Del Puente A, et al.: Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2002, 87:5058\u20135065.","journal-title":"J Clin Endocrinol Metab"},{"key":"98_CR42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/jc.2004-0509","volume":"90","author":"L Tauchmanov\u00e1","year":"2005","unstructured":"Tauchmanov\u00e1 L, Ricci P, Serio B, et al.: Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2005, 90:627\u2013634.","journal-title":"J Clin Endocrinol Metab"},{"key":"98_CR43","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1016\/j.transproceed.2009.07.018","volume":"41","author":"P Ahmadpoor","year":"2009","unstructured":"Ahmadpoor P, Reisi S, Makhdoomi K, et al.: Osteoporosis and related risk factors in renal transplant recipients. Transplant Proc 2009, 41:2820\u20132822.","journal-title":"Transplant Proc"},{"key":"98_CR44","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.biopha.2008.12.001","volume":"63","author":"M Vertemati","year":"2009","unstructured":"Vertemati M, Minola E, Dolci C, et al.: Gene expression, cytoskeletal changes and extracellular matrix synthesis in human osteoblasts treated with cyclosporin A. Biomed Pharmacother 2009, 63:619\u2013626.","journal-title":"Biomed Pharmacother"},{"key":"98_CR45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/bmt.2008.414","volume":"44","author":"YS Chae","year":"2009","unstructured":"\u2022\u2022 Chae YS, Kim JG, Moon JH, et al.: Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant 2009, 44:35\u201341. This is a pilot study on the use of zoledronic acid to prevent bone loss in allogeneic SCT recipients. In addition, it evaluated risk factors for bone loss in this population.","journal-title":"Bone Marrow Transplant"},{"key":"98_CR46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1651-2227.1994.tb13276.x","volume":"399","author":"SS Nussey","year":"1994","unstructured":"Nussey SS, Hyer SL, Brada M, et al.: Bone mineralization after treatment of growth hormone deficiency in survivors of childhood malignancy. Acta Paediatr Suppl 1994, 399:9\u201314; discussion 15. (Published erratum appears in Acta Paediatr Suppl 1995, 84:620).","journal-title":"Acta Paediatr Suppl"},{"key":"98_CR47","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0360-3016(92)90895-O","volume":"23","author":"SM Pierce","year":"1992","unstructured":"Pierce SM, Recht A, Lingos TI, et al.: Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992, 23:915\u2013923.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"98_CR48","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","volume":"147","author":"D Jia","year":"2006","unstructured":"Jia D, O\u2019Brien CA, Stewart SA, et al.: Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006, 147:5592\u20135599.","journal-title":"Endocrinology"},{"issue":"Suppl 1","key":"98_CR49","first-page":"33","volume":"58","author":"Z Hochberg","year":"2002","unstructured":"Hochberg Z: Mechanisms of steroid impairment of growth. Horm Res 2002, 58(Suppl 1):33\u201338.","journal-title":"Horm Res"},{"key":"98_CR50","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","volume":"327","author":"MC Chapuy","year":"1992","unstructured":"Chapuy MC, Arlot ME, Duboeuf F, et al.: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637\u20131642.","journal-title":"N Engl J Med"},{"key":"98_CR51","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042\u20134057. (Published erratum appears in J Clin Oncol 2004, 22:1351).","journal-title":"J Clin Oncol"},{"key":"98_CR52","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","volume":"100","author":"TH Diamond","year":"2004","unstructured":"Diamond TH, Higano CS, Smith MR, et al.: Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100:892\u2013899.","journal-title":"Cancer"},{"issue":"Suppl 3","key":"98_CR53","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","volume":"7","author":"JR Gralow","year":"2009","unstructured":"Gralow JR, Biermann JS, Farooki A, et al.: NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 2009, 7(Suppl 3):S1\u2013S32; quiz S33\u2013S35.","journal-title":"J Natl Compr Canc Netw"},{"key":"98_CR54","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"\u2022 Greenspan SL, Nelson JB, Trump DL, Resnick NM: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416\u2013424. This recent trial evaluated the efficacy of oral alendronate (using the US Food and Drug Administration-approved dosing regimen for osteoporosis) in preventing bone loss in prostate cancer patients treated with ADT. After 12\u00a0months, there were significant increases in BMD at the lumbar spine and hip.","journal-title":"Ann Intern Med"},{"key":"98_CR55","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","volume":"27","author":"SL Hines","year":"2009","unstructured":"Hines SL, Mincey BA, Sloan JA, et al.: Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009, 27:1047\u20131053.","journal-title":"J Clin Oncol"},{"key":"98_CR56","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al.: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840\u2013849.","journal-title":"Lancet Oncol"},{"key":"98_CR57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"AM Brufsky","year":"2009","unstructured":"Brufsky AM, Bosserman LD, Caradonna RR, et al.: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77\u201385.","journal-title":"Clin Breast Cancer"},{"key":"98_CR58","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008\u20132012.","journal-title":"J Urol"},{"key":"98_CR59","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1210\/jc.2006-0684","volume":"91","author":"AP Grigg","year":"2006","unstructured":"Grigg AP, Shuttleworth P, Reynolds J, et al.: Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006, 91:3835\u20133843.","journal-title":"J Clin Endocrinol Metab"},{"key":"98_CR60","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MPH.0b013e318142b7a1","volume":"29","author":"C Lethaby","year":"2007","unstructured":"Lethaby C, Wiernikowski J, Sala A, et al.: Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. J Pediatr Hematol Oncol 2007, 29:613\u2013616.","journal-title":"J Pediatr Hematol Oncol"},{"key":"98_CR61","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2008.20.5179","volume":"27","author":"K Visvanathan","year":"2009","unstructured":"Visvanathan K, Chlebowski RT, Hurley P, et al.: American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009, 27:3235\u20133258.","journal-title":"J Clin Oncol"},{"key":"98_CR62","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"MR Smith","year":"2004","unstructured":"Smith MR, Fallon MA, Lee H, Finkelstein JS: Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:3841\u20133846.","journal-title":"J Clin Endocrinol Metab"},{"key":"98_CR63","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"RS Matthew","year":"2009","unstructured":"\u2022 Matthew RS, Egerdie B, Hern\u00e1ndez Toriz N, et al.: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745\u2013755. This recent trial in prostate cancer showed an increase in BMD and reduction in fractures at 12, 24, and 36\u00a0months in patients treated with denosumab.","journal-title":"N Engl J Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0098-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0098-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0098-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:49:53Z","timestamp":1559436593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0098-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,1]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0098-x","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,1]]}}}